Abstract

1310O - Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

Full Text

Published Version

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
758P - Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis
J Llovet ... A.X Zhu
Annals of Oncology | VOL. 30
J Llovet, et. al.J Llovet ... A.X Zhu
01 Oct 2019
LBA19 - Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations
T.S.K Mok ... Y.-L Wu
Annals of Oncology | VOL. 30
T.S.K Mok, et. al.T.S.K Mok ... Y.-L Wu
01 Nov 2019
614P - Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer
...
Annals of Oncology | VOL. 30
, et. al. ...
01 Oct 2019
LBA38_PR - CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
...
Annals of Oncology | VOL. 30
, et. al. ...
01 Oct 2019
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Pembrolizumab Versus chemotherapy in microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study
T André ... L.A Diaz
Annals of Oncology | VOL. -
T André, et. al.T André ... L.A Diaz
01 Dec 2024
Author’s reply to the Letters to the Editor. Six years duration of adjuvant imatinib in high-risk GIST: more to come
J.-Y Blay ... A Le Cesne
Annals of Oncology | VOL. 35
J.-Y Blay, et. al.J.-Y Blay ... A Le Cesne
01 Dec 2024
Corrigendum to “Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma”: [Ann Oncol 35 (2024) 1039-1047]
T.M Kim ... S Luminari
Annals of Oncology | VOL. -
T.M Kim, et. al.T.M Kim ... S Luminari
01 Dec 2024
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors
A Di Federico ... J Luo
Annals of Oncology | VOL. -
A Di Federico, et. al.A Di Federico ... J Luo
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.